The European baseline series in 10 European Countries, 2005/2006:Results of the European Surveillance System on Contact Allergies (ESSCA) by Uter, Wolfgang et al.
  
 University of Groningen
The European baseline series in 10 European Countries, 2005/2006
Uter, Wolfgang; Rämsch, Christiane; Aberer, Werner; Ayala, Fabio; Balato, Anna;






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2009
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Uter, W., Rämsch, C., Aberer, W., Ayala, F., Balato, A., Beliauskiene, A., ... Schnuch, A. (2009). The
European baseline series in 10 European Countries, 2005/2006: Results of the European Surveillance
System on Contact Allergies (ESSCA). CONTACT DERMATITIS, 61(1), 31-38.
https://doi.org/10.1111/j.1600-0536.2009.01572.x
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Contact Dermatitis 2009: 61: 31–38 © 2009 John Wiley & Sons A/S
Printed in Singapore. All rights reserved CONTACT DERMATITIS
The European baseline series in 10 European
Countries, 2005/2006 – Results of the European
Surveillance System on Contact Allergies
(ESSCA)
Wolfgang Uter, Christiane Ra¨msch (Dept. of Med. Informatics, Biometry & Epidemiology, University of
Erlangen-Nu¨rnberg, Erlangen, Germany), Werner Aberer (Dept. of Dermatology, Medical University of Graz, Austria),
Fabio Ayala, Anna Balato (Dept. of Dermatology, Universita di Napoli Federico II, Napoli, Italy), Aiste
Beliauskiene (Dept. of Skin and Venereal Diseases, Kaunas University of Medicine, Kaunas, Lithuania), Anna Belloni
Fortina (Dermatology Unit, Dept. of Pediatrics, University of Padova, Italy), Andreas Bircher (Dept. of Dermatology,
Allergy Unit, University Hospital Basel, Switzerland), Jochen Brasch (Dept. of Dermatology, University of
Schleswig-Holstein, Campus Kiel, Germany), Mahbub M. U. Chowdhury (The Welsh Institute of Dermatology,
University Hospital of Wales, Cardiff, U.K.), Pieter-Jan Coenraads, Marie-Louise Schuttelaar (Dept. of
Dermatology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands), Sue Cooper
(Slade Hospital, Oxford, U.K.), Maria Teresa Corradin (Dermatology Unit, S. Maria degli Angeli Hospital, Pordenone,
Italy), Peter Elsner (Dept. of Dermatology and Allergology, Friedrich Schiller University, Jena, Germany), John S. C.
English (Dept. of Dermatology, The Queens Medical Centre, Nottingham, U.K.), Manige` Fartasch, Vera Mahler
(Dept. of Dermatology, University of Erlangen-Nu¨rnberg, Erlangen, Germany), Peter J. Frosch (Dept. of Dermatology,
Dortmund and University of Witten/Herdecke, Germany), Thomas Fuchs (Dept. of Dermatology, University of Go¨ttingen,
Germany), David J. Gawkrodger (Department of Dermatology, Royal Hallamshire Hospital, Sheffield, U.K.),
Ana-Maria Gime`nez-Arnau (Dept. of Dermatology, Hospital del Mar, IMAS. Universitat Auto´noma. Barcelona, Spain),
Cathy M. Green (Dept. of Dermatology, Ninewells Hospital and Medical School, Dundee, U.K.), Helen L. Horne
(James Cook University Hospital, Middlesbrough, U.K.) Riitta Jolanki (Control of Hypersensitivity Diseases, Finnish
Institute of Occupational Health (FIOH), Helsinki, Finland), Codagh M. King (The Royal Liverpool University Hospitals,
Liverpool, U.K.), Beata Kreˆcisz, Marta Kiec-Swierczynska (Dept. of Dermatology, Nofer Institute, Lodz, Poland),
Anthony D. Ormerod (Dept. of Dermatology, Aberdeen Royal Infirmary, U.K.), David I. Orton (Dept. of Dermatology,
Amersham Hospital, U.K.), Andrea Peserico (Dept. of Dermatology, University of Padova, Italy), Tapio Rantanen
(Dept. of Dermatology, Pa¨ija¨t-Ha¨me Central Hospital, Lahti, Finland), Thomas Rustemeyer (Dept. of Dermatology, Free
University of Amsterdam, The Netherlands), Jane E. Sansom (Dept. of Dermatology, Bristol Royal Infirmary, U.K.),
Dagmar Simon (Dept. of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland), Barry N. Statham
(Dept. of Dermatology, Abertawe Bromorgannwg University NHS Trust, Swansea, U.K.), Mark Wilkinson (Dept. of
Dermatology, the General Infirmary at Leeds, U.K.), Axel Schnuch (Information Network of Departments of
Dermatology (IVDK), University of Go¨ttingen, Germany)
Background: Continual surveillance based on patch test results has proved useful for the identification
of contact allergy.
Objectives: To provide a current view on the spectrum of contact allergy to important sensitizers across
Europe.
Patients/Methods: Clinical and patch test data of 19 793 patients patch tested in 2005/2006 in the 31
participating departments from 10 European countries (the European Surveillance System on Contact
Allergies’ (ESSCA) www.essca-dc.org) were descriptively analysed, aggregated to four European regions.
Results: Nickel sulfate remains the most common allergen with standardized prevalences ranging from
19.7% (central Europe) to 24.4% (southern Europe). While a number of allergens shows limited variation
across the four regions, such as Myroxylon pereirae (5.3–6.8%), cobalt chloride (6.2–8.8%) or thiuram
mix (1.7–2.4%), the differences observed with other allergens may hint on underlying differences in
exposures, for example: dichromate 2.4% in the UK (west) versus 4.5–5.9% in the remaining EU
regions, methylchloroisothiazolinone/methylisothiazolinone 4.1% in the South versus 2.1–2.7% in the
remaining regions.
Conclusions: Notwithstanding residual methodological variation (affecting at least some ‘difficult’
allergens) tackled by ongoing efforts for standardization, a comparative analysis as presented provides (i)
a broad overview on contact allergy frequencies and (ii) interesting starting points for further, in-depth
investigation.
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Past experience has shown that clinical surveillance
of contact allergy, i.e. systematic analysis of patch
test data, is a prerequisite for the identification
and, ultimately, the control of contact allergy epi-
demics (1). As these often start locally or nationally,
continual analysis should not only focus on global
trends but also on possible differences between, e.g.
European regions to derive valuable starting points
for the in-depth investigation of possible unaccept-
able exposures. On a European level, the ‘European
Surveillance System on Contact Allergies’ (ESSCA;
www.essca-dc.org) has proved useful in provid-
ing current information on the spectrum of contact
allergy across Europe in the countries participat-
ing (2, 3). The present analysis of 2005/2006 patch
test data aims at providing an update.
Methods
Background information on the objectives and meth-
ods of the ESSCA has been reported (2). Briefly,
patch test results obtained with the European Base-
line Series and selected other allergens also tested
in consecutive patients, e.g. in local or national
adaptations of the European Baseline Series, were
collected along with basic demographic and clinical
data. After import from the various patch test soft-
ware databases, including ‘WinAlldat/ESSCA’ (4),
internal reports were delivered to each centre to be
checked for completeness and plausibility. If feed-
back necessitated amendments, these were made
before pooling data for the analyses presented. As
a compromise between a global and a very detailed
results presentation on the level of single depart-
ments, a regional aggregation within Europe was
chosen with the ‘western’ region equivalent to the
UK, but otherwise grouping several countries in one
region (Table 1).
Routine patch test exposure time was 2 days,
except in Kiel, Germany, where it was 1 day. Patch
test results were recorded according to interna-
tional guidelines (5). The standard ‘positive out-
come’ (allergic reaction) of the patch test was
defined as a morphologically + to +++ reaction (5)
between D3 and D5 after the application of the patch
test which was not, upon final evaluation, considered
irritant. Descriptive analysis of data followed current
guidelines as elaborated by ESSCA (6), in particular
employing age- and sex-standardization of sensiti-
zation prevalences (7). For data management and
descriptive analysis, the statistical software package
SAS™ (version 9.1, SAS Institute, Cary, NC, USA)
was used.
Results
In the 31 participating departments 9695 patients
were patch tested in the year 2005 in the course
of 9767 consultations, and 10 293 patients were
tested in 2006, in the course of 10 366 consultations
(Table 1), i.e. a small proportion of patients was
seen and patch tested more than once. In these cases,
the most current consultation was chosen for analy-
sis. In the following analyses, the 2 years are aggre-
gated. The median number of patients per clinic
was 608 in the 2 years. With 240 and 110 patients,
respectively, Middlesbrough, UK and Bern, Switzer-
land contributed the lowest number of patients (in
2006 only). The largest number of patients consulted
the departments in Amsterdam, The Netherlands and
Leeds, UK (1558 and 1537 patients, respectively).
Among the 31 departments, one department is spe-
cialized in paediatric dermatology (Padova ‘Pedia-
tria’, Italy). Because of its restricted age range (all
patients less than 18 years old, see Ref. (3)), and
in view of the fact that many allergens exhibit a
strong association with age, the results of this spe-
cialized department are not included in the further
analyses presented in this paper but will be reported
elsewhere.
The distribution of important demographic vari-
ables according to the MOAHLFA index in the four
regions is shown in Table 2. While the proportion of
male patients is relatively similar, other patient char-
acteristics differ more – most markedly the propor-
tion of patients with occupational dermatitis, diag-
nosed upon final evaluation (see Discussion). The
age distribution showed some differences, with the
youngest patients tested in the south (median age
39, inter-quartile range [IQR] 26–56) and the old-
est in central Europe (median age 45 years, IQR
32–58), the western (median 43 years, IQR 29–58)
and north-eastern (median 42 years, IQR 30–52)
regions occupying an intermediate rank.
In 25 of the 31 centres at least 95% of the
patients were tested with the European Baseline
Series (8), as locally or nationally adapted, in five
centres between 90% and 95%. In one centre only
(Erlangen, Germany) slightly fewer than 90% of
the patients were tested to this series. The propor-
tion of patients with positive reactions to at least
one allergen of the European Baseline Series among
those tested with this series as used in the respec-
tive department displayed considerable variability
between centres, but was very similar across regions
(Table 1). The patch test results with the European
Baseline Series in the 30 departments, aggregated
to four regions, are shown in Table 3, the allergens
grouped into different classes (fragrances, metals,
preservatives, rubber allergens, a few ‘diverse’ aller-
gens and topical agents). The number of patients
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Amersham UK-01 HT, CH 1038 1061 41.6
Nottingham UK-02 HT, CH 926 926 45.2
Oxford* UK-04 HT, CH 372 372 42.2
Sheffield UK-05 HT, CH 808 808 42.0
Dundee UK-07 HT, CH 919 919 35.9
Leeds UK-08 HT, CH 1537 1537 36.8
Aberdeen UK-09 HT, CH 605 605 62.5
Bristol UK-10 HT, CH 613 613 44.5
Liverpool UK-11 HT, CH 618 618 49.5
Middlesbrough∗ UK-12 HT, CH 240 240 59.6
Swansea UK-30 HT, CH 344 344 44.5
Cardiff UK-31 HT, CH 584 584 36.8
West 8604 8627 43.1
Barcelona ES-01 HT, CH 751 755 43.5
Napoli IT-01 CH 708 708 36.1
Padova IT-02 CH 895 895 52.7
Padova Ped. IT-03 CH 648 648 30.6
Pordenone IT-06 CH 431 431 41.1
South 3240 3240 41.5
Groningen NL-01 TT 784 793 41.8
Amsterdam-VU NL-02 HT, CH 1558 1582 42.7
Basel CH-42 TT, HT 517 535 47.3
Bern∗ CH-56 HT 110 112 56.5
Graz AT-25 HT 660 660 50.9
Dortmund DE-01 HT 593 602 31.1
Go¨ttingen DE-03 HT 258 261 37.1
Kiel DE-06 HT 470 472 48.8
Jena DE-12 HT 672 696 40.4
Erlangen DE-24 HT 683 744 50.1
Central 6305 6457 43.7
Helsinki FI-01 HT, CH 296 297 42.1
Lahti FI-02 CH 465 465 50.3
Kaunas LT-01 HT 242 242 46.3
Lodz PL-01 CH 608 608 39.1
Northeast 1611 1612 44.0
#HT = Trolab™ (Almirall-Hermal, Reinbek, Germany), CH = Chemotechnique Diagnostics™ (Malmo, Sweden), TT = True test®.
§Consultation is the presentation of a patient for patch testing, possibly multiply during a period.
∗2006 only.
tested varies within regions, because of differ-
ent compositions of the local standard series in
the departments aggregated, or because allergens
have been withdrawn or added to the series dur-
ing the study period, such as hydroxyisohexyl
3-cyclohexene carboxaldehyde (e.g. Lyral®) or the
fragrance mix II. Regarding methyldibromo gluta-
ronitrile, a subset of ‘central’ patients had initially
(also) been tested with 0.2% in petrolatum, yield-
ing 3.0% [95% confidence interval (CI): 2.3–3.7%]
standardized positive reactions.
The temporary addition of allergens to a Baseline
series (locally or in a contact allergy network) can
give clues on its potential to become a permanent
part of the Baseline series. Among those allergens
tested in consecutive patients in more than one
region, 2-bromo-2-nitropropane-1,3-diol (bronopol)
yielded 1.1% and 1.2% positive reactions in the
‘West’ (tested 0.25% pet.) and the ‘Central’ region
(tested 0.5% in pet.), respectively appears to be a
candidate for inclusion.
Discussion
The present descriptive analysis of contact allergy
prevalences in patients patch tested for suspected
allergic contact dermatitis throughout many, albeit
not all, European countries differs from the preced-
ing report, which contrasted global contact allergy
prevalences (and MOAHLFA characteristics) with
local minima and maxima (3): In an attempt to
reduce the impact of inter-departmental variation in
patient characteristics and the potential for variation
in interpretation of positive reactions several centres
have now been aggregated to regions. This reduced
the amount of variation and yielded a more stable
picture. As a trade-off, local clustering of contact
allergy to specific allergens cannot be recognized.
However, supplementary centre-wise reports from
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Table 2. MOAHLFA percentages in the four regions (average percentage and range)
West South Central Northeast
2005/2006 (n = 8604) (n = 2590) (n = 6310) (n = 1611)
Male M 32.9 (UK-11:
28.6 – UK-31: 34.9)
33.8 (ES-01:
29.6 – IT-06: 36.9)
37.5 (AT-25:
31.8 – DE-01: 48.1)
32.8 (LT-01:




4.1 – UK-30: 17.4)
4.4 (IT-02,06:
3.0 – ES-01: 13.7)
18.8 (DE-06:
9.4 – NL-01: 26.2)
37.0 (FI-02:
30.5 – FI-01: 55.1)
Atopic dermatitis A § 11.8 (IT-02:
6.9 – IT-01: 17.2)
23.4 (DE-06:
7.2 – NL-01: 39.0)
25.1 (PL-01:




20.0 – UK-30: 48.0)
25.6 (ES-01:
14.5 – IT-06: 33.0)
26.1 (AT-25:
14.2 – CH-56: 42.7)
46.2 (LT-01:
23.6 – FI-01: 74.3)
Primary site: Leg L 7.6 (UK-12:
3.3 – UK-04: 11.3)
8.1 (IT-01: 5.1 - IT-02:
11.0)
8.4 (NL-01:
4.9 – DE-06: 17.5)
2.7 (FI-01:




15.7 – UK-02: 31.9)
15.9 (IT-01:
12.4 – IT-06: 22.0)
16.0 (CH-56:
8.2 – NL-01: 22.8)
18.7 (FI-01:
13.2 – LT-01: 38.4)
Age, above 40 A 57.3 (UK-31:
51.5 – UK-12: 63.3)
49.1 (IT-01:
40.7 – ES-01: 65.6)
61.2 (NL-01:
49.1 – DE-06: 74.0)
55.9 (LT-01:
52.1 – FI-02: 57.9)
§The historical data particularly on atopic dermatitis has not been recorded by the British Contact Dermatitis Society (only atopy in general)
(Amersham, UK: 4.1%).
Departments with missing data (10% for sex and age; 20% for all other categories) were excluded from the analysis of the respective item.
Additionally ‘partial’ occupational contribution was noted in Lahti, Finland (19.8%); Groningen, The Netherlands (9.5%); Amsterdam, The
Netherlands (8.3%); Barcelona, Spain (0.9%) and Kaunas, Lithuania (0.8%).
Only past atopic dermatitis was considered.
In departments with more than 20% missing data for primary site, the first site to the first final diagnosis was considered equivalent for
this analysis.
See Table 1 for departments aggregated to the regions. Padova ‘Pediatria’, Italy not included.
the contributing national contact dermatitis groups
can compensate for this (e.g. Ref. (9)).
Still, focussing first on the patient characteristics
according to the MOAHLFA index, remarkable dif-
ferences persisted. As mentioned above, the special-
ization of two of four ‘north-eastern’ departments
in occupational dermatology [Finnish Institute of
Occupational Health (FIOH), Helsinki, Finland and
Nofer Institute, Lodz, Poland] has a strong impact
on the MOAHLFA index, with a very high pro-
portion of occupational dermatitis (2004 average:
14.3%) and hand dermatitis (2004 average: 32.9%),
see Table 2. In the UK patients with facial dermatitis
are over-represented compared with the remaining
regions, while the proportion of patients with der-
matitis affecting the leg and hand and male patients
is very similar. The proportion of patients aged 40
and above is high among the ‘central’ European
patients, mostly due to the German patients (10). As
many allergens exhibit an age gradient – positive,
e.g., the fragrance mix (11, 12), or negative, as in
case of nickel (13) –an age distribution differing
across space (as here) or over time may confound
comparisons. Hence, the contact allergy prevalences
have been standardized for age and sex in this anal-
ysis, following pertinent guidelines (6).
The European Baseline Series is continually being
adapted by a working group of the European Soci-
ety of Contact Dermatitis (ESCD). During the study
period, the latest addition had been methyldibromo
glutaronitrile, recommended to be tested at 0.5%
in pet. (14). While this allergen had indeed been
included by most ESSCA participants, the most
common test concentration was 0.3%. About 3 years
later, the fragrance mix II (14% pet.) and hydroxy-
isohexyl 3-cyclohexene carboxaldehyde (5% pet.)
have been included in the recommendation (8). As
these allergens, in particular hydroxyisohexyl 3-
cyclohexene carboxaldehyde, have been tested by
several groups starting in 2005 or 2006 (earlier in
some centres) already, the present analysis is able
to confirm the necessity to include these important
fragrance allergens in the European Baseline Series
in terms of a high contact allergy prevalence. With
respect to the metal allergens the regionally aggre-
gated prevalences of contact allergy to nickel appear
remarkably similar, and to average out between-
centre differences (even within regions) previously
noted (3). In contrast, patch test results with cobalt
and particularly with chromate diverge more, with
the contact allergy prevalence to chromate being sig-
nificantly lower in the UK (‘western’ region) than
in each of the other three regions. This observation
may warrant further investigation.
Some allergens such as p-phenylenediamine,
Myroxylon pereirae resin, thiuram mix or budes-
onide yielded very similar contact allergy fre-
quencies, which may illustrate fairly homogenous
exposure across Europe. In case of other allergens
outliers are observed:
• Contact allergy to lanolin (wool alcohol) is sig-
nificantly more common in ‘central’ Europe
than in the remaining regions – be it due resid-
ual
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confounding by higher age, or differing spe-
cific reading standards (which may, of course,
explain some amount of variation in case of
other allergens as well).
• The prevalence of contact allergy to methyl-
dibromo glutaronitrile (tested 0.3%) showed
marked variation across Europe, but also nation-
ally (9) which seems hard to explain, assuming
that the main exposure via leave-on and rinse-
off cosmetics is fairly homogenous due to a
European market of these products. However,
methyldibromo glutaronitrile can probably be
regarded a declining allergen (15).
• Methylchloroisothiazolinone/methylisothiazoli-
none has achieved a relatively stable contact
allergy prevalence of around 2%, notwithstand-
ing some between-centre variation (3, 9) or
decreases noted in some parts of Europe (16).
However, in the ‘south’ contact allergy to this
preservative is still significantly more common,
which may warrant investigation of possible
sensitizing exposures.
• Neomycin sulfate is still (slightly) above 1%
positive patch test reactions in consecutively
tested patients and thus qualifies as part of the
European Baseline Series. However, at least in
Germany, it is not available as over-the-counter
drug, prescriptions decrease and, accordingly,
contact allergy prevalence decreases (17).
• In contrast to budesonide, contact allergy fre-
quencies to tixocortol-21-pivalate varied sig-
nificantly as has also been found in previ-
ous studies (reviewed in Ref. (18)). It has
been pointed out that the corticosteroids should
best be read at D7 of the test, so with the
presently employed reading frame (D3–D5)
some false-negative results may be expected
(18). Moreover, the issue of the ideal test con-
centration does not seem to be settled: regarding
tixocortol-21-pivalate, the British Contact Der-
matitis Society recommends (19) and uses 1%
instead of 0.1%.
It has been stated that the contact allergy preva-
lence in consecutively tested patients should nor-
mally exceed 0.5–1% for an allergen to be eligi-
ble for inclusion in the Baseline series (20). From
this background and other considerations as well,
clioquinol could be removed from this [also (3,
16)], while other, overall rare, sensitizers are at
least regionally more important, such as primin or
N-isopropyl-N ′-phenyl-p-phenylenediamine (IPPD).
Conclusion
The 2005/2006 results provide an up-to-date view
on the prevalence of contact allergy to aller-
gens of the (European) Baseline Series across
Europe. Methodological differences may contribute
to between-centre, possibly also to between-country,
variation. Hence, methods to standardize applica-
tion and reading, and to monitor the reproducibility
of reading and interpretation of patch test results
within national and international contributors to con-
tact dermatitis databases should be (further) devel-
oped. Still, the comparison potentially offers start-
ing points for the in-depth investigation of possible
causes of contact allergy in those areas particularly
affected.
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